BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 6, 2016
View Archived Issues
Shire reports milestones of first quarter 2016
Read More
AstraZeneca reports results of first quarter 2016
Read More
Concert Pharmaceuticals developing CTP-543 for alopecia areata
Read More
NicOx's NO-donating travoprost derivative in models of ocular hypertension
Read More
CLG-561 for AMD
Read More
Anti-c-Met antibody-drug conjugate from Sorrento to enter IND-enabling studies
Read More
TEASE: early phase II data for ALK-001
Read More
First clinical results for CFI-400945 show signs of activity in patients with solid tumors
Read More
WAVE Life Sciences and Pfizer agreement for development of optimized therapeutics
Read More
Audentes Therapeutics forms partnerships to advance AAV therapy for Crigler-Najjar syndrome
Read More
Seres Therapeutics enters agreements fro microbiome therapeutics for IBD
Read More
Wellcome Trust award to advance development of Kineta's Lassa fever treatment
Read More
Opthea gives update on phase IIa dose-expansion study of OPT-302 in wet AMD
Read More
New results from Conatus' phase II study of emricasan in liver cirrhosis
Read More
NS4B inhibitor YF-01 demonstrates efficacy in a hamster model of YFV infection
Read More
Combination cancer vaccine CMB-305 named FDA orphan treatment for soft tissue sarcoma
Read More
Shenzhen University patents piscidin analogues
Read More
Bristol-Myers Squibb discloses PD-1/CD80 interaction inhibitors
Read More
Novo Nordisk reports GLP-1 analogues
Read More
Merck & Co. presents HIF prolyl hydroxylase inhibitors
Read More
Redx Pharma introduces Wnt signaling and PORCN inhibitors
Read More
Ligand acquires rights to several programs from medical device company
Read More
Novel FASN inhibitors demonstrate efficacy in NSCLC and CRC models
Read More
Merus announces dosing of first patient in phase I/II trial of MCLA-117 in patients with AML
Read More
Medivation reiterates rejection of Sanofi proposal
Read More
FDA advisory committee votes on KemPharm's Apadaz
Read More
NIH grant supports Scripps' development of RNA-based therapeutics
Read More
Phase III trials of tildrakizumab in moderate to severe plaque psoriasis meet primary endpoints
Read More
Sirnaomics obtains funding to support fibrosis programs
Read More
Clovis terminates rociletinib studies, withdraws MAA, according to Q1 2016 overview
Read More